icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
C1zvWUbzztPhT03R